Navigation Links
Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/3/2008

mely manner; our need for capital, risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug be found safe and effective after extensive clinical trials; our dependence on suppliers, collaborative partners and other third parties and the prospects and timing for negotiating supply agreements, corporate collaborations or licensing arrangements; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at http://www.sedar.com.

Assumptions underlying our expectations regarding forward-looking statements or information contained in this press release include, among others, that we will raise enough capital, on reasonable terms and in a timely manner; that we will retain our key personnel; that we will obtain the necessary regulatory approvals related to HspE7 and our adjuvant in a timely manner; that enough HspE7 will be available to conduct our planned trials; that we will be able to procure the necessary amount of adjuvant to conduct our planned trials; that we will obtain timely approval from additional IRBs; that the results from additional preclinical and clinical work, if any, will be consistent with the results we have already obtained; that a sufficient number of patients will be available to conduct our planned trials; and that sufficient data will be generated to support our IND.

In the event that any of these assumptions prove to be incorrect, or in the event that we are impacted by any of the risks identified above, we may not be able to continue in our business as planned.

F
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating ... Inc. ("Advaxis" or the "Company") (NASDAQ: ADXS ... duties to shareholders. On January 21, 2015, ... that Advaxis had misrepresented the clinical data for its ...
(Date:1/23/2015)... 23, 2015  Now available for sale, The Armor1 Ankle ... prevents ankle sprains by cushioning the ankle from an ... around the outside of any shoe type and allows ... still offering protection against sprains. With customers in physical ...
(Date:1/23/2015)... , Jan. 23, 2015 Cord Blood America, Inc. ( ... or the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, ... today, and provides an update for shareholders detailing why a ... requested. Dear Shareholders, As we reflect ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 As interest ... overall health care gains momentum worldwide, Rev. Eric J. ... HealthCare Chaplaincy Network (HCCN), will be the keynote speaker ... care in Israel’s public health system. , The conference, “Hope ...
(Date:1/22/2015)... released a new blog post presenting a list of vehicles that ... , Some types of vehicles cannot be covered under an ordinary ... to see if their vehicle qualifies for auto insurance coverage. ... cars that cannot be covered by a plan. Clients have little ...
(Date:1/22/2015)... 22, 2015 Step into a macabre ... Science Museum of Virginia. Wicked Plants, the Museum’s latest ... unearths 75 poisonous, carnivorous and diabolical plants inside of ... to uncover the biochemical, physical and neurological processes between ...
(Date:12/26/2014)... The US represents the largest market for CRC across the ... that sales of branded therapies were $2.23 billion. The US ... of the disease, high drug treatment rate, and higher drug ... of CRC therapies over the forecast period will be driven ...
(Date:12/26/2014)... Cooking and warming equipment has a buyer ... slightly positive negotiation conditions for buyers, stemming from a low ... level of price volatility. “However, buyer power is reduced by ... and high volatility in the world price of steel and ...
Breaking Medicine News(10 mins):Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3
... , FRIDAY, July 15 (HealthDay News) -- Injection ... treatment, regardless of what types of drugs they use, ... drug users suffer higher rates of abuse, dependence and ... could help treatment programs specialize their care to target ...
... Reporter , FRIDAY, July 15 (HealthDay News) -- New research ... that protects against hundreds of strains of meningococcus B ... Bacterial meningitis, an inflammation of the membranes covering the brain ... vaccines cover four of five types of bacteria that cause ...
... male baboons exhibit higher levels of stress hormones than ... a social hierarchy may be more costly than previously ... researchers, for the first time, identified higher levels of ... to beta males. "These results are very interesting ...
... Reinberg HealthDay Reporter , THURSDAY, July 14 (HealthDay News) ... that include smoking has dropped for the fifth year in a ... nearly 72 percent drop since 2005 in smoking images in movies ... smoking to 595 in 2010. In addition, the average number of ...
... , FRIDAY, July 15 (HealthDay News) -- In an ... number of governments have raised taxes on cigarettes, yet many ... new Canadian study. But the public health measure has ... the researchers recently reported in the International Journal of ...
... and Rome (July 15, 2011): The Lancet , a ... emphasizes the critical role of expanding access to HIV treatment ... pandemic. , The publication of the editorial comment coincides ... Pathogenesis, Treatment and Prevention (IAS 2011) taking place in Rome, ...
Cached Medicine News:Health News:Injection Drug Users Most in Need of Treatment, Study Says 2Health News:Researchers Closer to Developing Universal Meningitis B Vaccine 2Health News:Researchers Closer to Developing Universal Meningitis B Vaccine 3Health News:Less Lighting Up in Movies Aimed at Kids 2Health News:Less Lighting Up in Movies Aimed at Kids 3Health News:Cigarette Tax Unlikely to Deter Some Smokers: Report 2Health News:Roll out treatment as prevention now to stop HIV and AIDS 2
... The Minimally Invasive Hip Instruments ... THA through a mini-incision using ... set of instruments helps reduce ... invasive THA by optimizing exposure ...
The Endotrac™ System includes an Obturator, Slotted Cannula, Synovial Elevator, Ligament Probe, Ligament Rasp, Blade Handle, two Retractors and sterilizable tray. The Endotrac&trade....
Instrument set for carpal tunnel release....
Standard arthroscopy graspers for small joints. Also available are Mosquito Tip Graspers, 45 degree Forceps, SquareTrimmer Blunt Tip Forceps and SST Scoop Tip Forceps....
Medicine Products: